Inhibition of omeprazole induced hypergastrinaemia by SMS 201-995, a long acting somatostatin analogue in man

• Published in: Gut Vol. 34; no. 9; pp. 1186 - 1190
• Main Authors: Meijer, J L, Jansen, J B, Crobach, L F, Biemond, I, Lamers, C B
• Format: Journal Article Conference Proceeding
• Language: English
• Published: London BMJ Publishing Group Ltd and British Society of Gastroenterology 01-09-1993; BMJ; BMJ Publishing Group LTD
• Subjects: Adult; Biological and medical sciences; Drug Administration Schedule; Female; Gastrins - blood; Hormones. Endocrine system; Humans; Male; Medical sciences; Octreotide - administration & dosage; Octreotide - pharmacology; Omeprazole - adverse effects; Omeprazole - antagonists & inhibitors; Pepsinogens - blood; Pharmacology. Drug treatments; Human; Chemotherapy; Treatment; Enzyme; Analog; Enzyme inhibitor; Digestive diseases; Inhibition; Somatostatin; Comparative study
• ISSN: 0017-5749; 1468-3288; 1458-3288
• DOI: 10.1136/gut.34.9.1186

Whether the long acting somatostatin analogue SMS 201-995 (octreotide, Sandostatin) could inhibit the basal and meal stimulated hypergastrinaemia and hyperpepsinogenaemia induced by omeprazole was investigated. Eight healthy subjects were randomised to receive five day courses of SMS 201-995 (25 micrograms subcutaneously three times daily), omeprazole (40 mg once a day), a combination of both drugs, or placebo. Basal and meal stimulated serum gastrin and basal serum pepsinogen A and C values were measured the day before treatment, on day five of treatment, and the day after each course of treatment. Omeprazole caused significant increases in basal and meal stimulated peak and integrated serum gastrin values and pepsinogen A and C levels, which were still significantly raised the day after stopping omeprazole treatment. Giving SMS 201-995 with omeprazole significantly reduced any omeprazole induced increases in basal and meal stimulated peak and integrated serum gastrin levels; serum pepsinogen A and C values were significantly inhibited too. Serum gastrin values during combined therapy were not significantly different from those during placebo treatment, whereas pepsinogen A and C levels were still significantly raised. On the day after stopping combined therapy, basal and meal stimulated peak and integrated serum gastrin and serum pepsinogen C (but not pepsinogen A) levels were not significantly different from values obtained on the day after stopping omeprazole alone. SMS 201-995 without omeprazole significantly inhibited basal and meal stimulated peak and integrated serum gastrin levels. Pepsinogen A was also significantly inhibited by SMS 210-995, but the reduction in pepsinogen C failed to reach statistical significance. In conclusion, SMS 201-995 prevents basal and meal stimulated increases in serum gastrin during omeprazole therapy. This finding may have clinical importance in the few patients who have pronounced hypergastrinaemia because of profound long acting acid inhibition.